ストックスクリーナーアプリを入手
10.09
0.10%
0.010
前日終値:
$10.08
開ける：
$10.04
24時間の取引高:
425.85K
Relative Volume:
0.88
時価総額：
$195.15M
収益：
$1.54M
当期純損益:
$-84.53M
株価収益率:
-1.7353
EPS:
-5.8145
ネットキャッシュフロー:
$-73.65M
1週間 パフォーマンス:
-0.79%
1か月 パフォーマンス:
+11.74%
6か月 パフォーマンス:
+33.47%
1年 パフォーマンス:
+4.78%
1日の値動き範囲:
$9.88
$10.29
1週間の範囲:
$9.365
$10.39
52週間の値動き範囲:
$7.12
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
名前
Corbus Pharmaceuticals Holdings Inc
セクター
電話
617-963-0103
住所
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
10.09 | 188.77M | 1.54M | -84.53M | -73.65M | -5.8145 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-07-30 | 開始されました | Wedbush | Outperform |
| 2024-07-22 | 再開されました | H.C. Wainwright | Buy |
| 2024-06-26 | 開始されました | B. Riley Securities | Buy |
| 2024-06-03 | 繰り返されました | Oppenheimer | Outperform |
| 2024-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-03-06 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-08 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-08 | ダウングレード | Jefferies | Buy → Hold |
| 2020-09-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-03-26 | 開始されました | Nomura | Buy |
| 2019-04-05 | 開始されました | Jefferies | Buy |
| 2019-03-20 | 開始されました | Oppenheimer | Outperform |
| 2019-01-11 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-10-24 | 開始されました | B. Riley FBR | Buy |
| 2018-01-19 | 開始されました | Raymond James | Outperform |
| 2017-12-14 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 繰り返されました | Noble Financial | Buy |
| 2017-09-29 | 再開されました | Noble Financial | Buy |
| 2017-03-30 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-11-11 | 繰り返されました | Noble Financial | Buy |
すべてを表示
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
Corbus Pharmaceuticals (CRBP): Citadel entities and Kenneth Griffin disclose 1.1% stake - stocktitan.net
Price-Driven Insight from (CRBP) for Rule-Based Strategy - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates - Investing.com
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates By Investing.com - Investing.com Australia
CRBP Insider Buying: Chief Business Officer Nishant Saxena Purch - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $33 - moomoo.com
Corbus Pharmaceuticals (NASDAQ:CRBP) Insider Buys 2,600 Shares of Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Research Analysts Set Expectations for CRBP Q3 Earnings - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Corbus Pharmaceuticals (CRBP) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) CEO Yuval Cohen Sells 17,000 Shares of Stock - MarketBeat
Sean Moran Sells 12,000 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc Actuals & Estimates (NASDAQ:CRBP) - TradingView
Corbus Pharmaceuticals (NASDAQ:CRBP) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock News Today - TradingKey
CRBP (NASDAQ: CRBP) insider plans 12,000-share sale via Stifel - stocktitan.net
CRBP (CRBP) holder files to sell 17,000 Nasdaq-traded shares - stocktitan.net
CRBP Maintained by Oppenheimer -- Price Target Lowered to $48.00 - GuruFocus
Oppenheimer Issues Pessimistic Forecast for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat
CRBP Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating - marketscreener.com
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $35 - moomoo.com
HC Wainwright Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat
William Blair Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating - moomoo.com
Form 8K Corbus Pharmaceuticals Holding For: 6 August By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals (NASDAQ: CRBP) ramps R&D to $51M as cash backs key trials - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update - The Manila Times
Corbus Pharmaceuticals (NASDAQ: CRBP) doubles Q2 loss while securing FDA clearance for Phase 3 trial - Stock Titan
Corbus Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com
Corbus Pharmaceuticals (CRBP) Earnings Date and Reports 2026 - MarketBeat
Corbus Pharmaceuticals (CRBP) Holds Gains as Biotech Momentum BuildsCall Wall - dars.gov.et
Corbus Pharmaceuticals Announces Last Patient Last Visit In Canyon-1 Study Of CRB-913 For The Treatment Of Obesity - marketscreener.com
Corbus Pharmaceuticals (CRBP) Completes Final Patient Visit in C - GuruFocus
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Corbus Pharma CMO Nicacio Leonardo Viana files initial beneficial ownership statement - Bitget
Obesity Treatment Study Reaches Final Visit; Corbus Data Expected in September - stocktitan.net
CRBP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity - Yahoo Finance
Corbus Pharmaceuticals Holdings Stock Price Forecast. Should You Buy CRBP? - StockInvest.us
Corbus Pharmaceuticals Holdings Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Corbus Pharmaceuticals Holdings Inc (CRBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals (CRBP) Gains FDA Nod for Pivotal CRB-701 - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. initiates FDA-cleared registrational study for CRB-701 in oropharyngeal cancer - Traders Union
FDA clears Corbus registrational trial for head and neck cancer drug - Investing.com Nigeria
Corbus Pharmaceuticals Holdings Inc (CRBP) 財務データ
収益
当期純利益
現金流量
EPS
Corbus Pharmaceuticals Holdings Inc (CRBP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Cohen Yuval | Chief Executive Officer |
Aug 07 '26 |
Sale |
10.08 |
17,000 |
171,396 |
157,316 |
| Moran Sean F. | Chief Financial Officer |
Aug 07 '26 |
Sale |
10.08 |
12,000 |
120,971 |
84,694 |
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):